Growth of 40% per annum continues for AFT Pharmaceuticals in the Australasian market (Australia and NZ) with sales for this year due to break $22 million per annum.
AFT Group Sales Growth continues at +40%
Similar articles
Dispute with PBL Solutions Limited
AFT Pharmaceuticals Limited [NZX: AFT; ASX: AFP] advises that British Virgin Islands incorporated PBL Solutions Limited, the 35% shareholder in AFT’s 65% owned subsidiary AFT Orphan Pharmaceuticals Limited, has filed legal proceedings in the New Zealand High Court against AFT and Dr Hartley Atkinson. AFT disclosed this as a potential claim in its FY2020 results announcement dated 20 May 2020 and also in the notes to its FY2020 financial statements.
Read more
AFT introduces new HYLO-FRESH and HYLO-FORTE
AFT Pharmaceuticals is pleased to announce the launch of new HYLO®-FRESH and HYLO- FORTE® eye drops to the Australian market.
Read more
Further European approval puts Maxigesic on path to become leading global paracetamol-ibuprofen painkiller
Chief Executive of AFT Pharmaceuticals, Dr Hartley Atkinson, says that having regulatory approval for these 9 additional countries will open up significant opportunities for global Maxigesic sales.
Read more